X
Category:
Memoirs
Up the Creek with a Paddle: Beat MS and All
Up the Creek with a Paddle: Beat MS and All
Up the Creek with a Paddle: Beat MS and All
Up the Creek with a Paddle: Beat MS and All

Up the Creek with a Paddle: Beat MS and All Autoimmune Disorders with Low Dose Naltrexone (LDN)

Product ID : 8200167
4.4 out of 5 stars


Galleon Product ID 8200167
Shipping Weight 0.67 lbs
I think this is wrong?
Model
Manufacturer Outskirts Press
Shipping Dimension 8.5 x 5.51 x 0.51 inches
I think this is wrong?
-
1,727

*Price and Stocks may change without prior notice
*Packaging of actual item may differ from photo shown
  • Electrical items MAY be 110 volts.
  • 7 Day Return Policy
  • All products are genuine and original
  • Cash On Delivery/Cash Upon Pickup Available

Pay with

Up the Creek with a Paddle: Beat MS and All Features

  • Used Book in Good Condition


About Up The Creek With A Paddle: Beat MS And All

"In 1986, when I first discovered LDN, if I had Mary Boyle Bradley on my team, this drug would have been approved, marketed and manufactured by a reputable pharmaceutical company. I have no doubt about that." Dr. Bernard Bihari The story is simple. It is about love, life and hope. After years of battling with the onslaught of her husband's Primary Progressive Multiple Sclerosis, Mary stumbled on a little known doctor in New York City, Dr. Bernard Bihari. Many people on the internet claimed that Dr. Bihari knew how to stop every type of MS from progressing. Even better, it was claimed that he could help everyone with an autoimmune disorder, ranging from psoriasis to AIDS. It was claimed that Dr. Bihari could help them with Low Dose Naltrexone (LDN). Eventually, Mary's husband took a leap of faith and put Dr. Bihari's work to the test. LDN worked. It stopped his MS from progressing. Since September 2002, a worldwide campaign has ignited with passionate momentum to get LDN medically recognized as a treatment for MS and all autoimmune disorders. LDN is a cheap, generic, out of patent drug with no known side-effects. Despite the fact that there is no financial incentive to entice any pharmaceutical company to investigate new uses for Naltrexone, the ambition is for LDN to hit the masses and improve the lives of millions. Small scale LDN clinical trials are finally making progress across the globe and are paving the way for a much better future for everyone who suffers from an autoimmune disorder.